Publications by authors named "H Klitgaard"
Article Synopsis
- * Current treatments mainly provide symptom relief, and effective therapies to modify the disease and protect neurons are limited.
- * The nuclear factor-erythroid 2-related factor 2 (NRF2) plays a key role in defending cells from damage, making it a promising target for new treatments aimed at addressing neurodegeneration's root causes.
Objectives: This review aims to analyse the published data on preclinical and human experimental and clinical adenosine modulation for pain management. We summarise the translatability of the adenosine pathway for further drug development and aim to reveal subgroups of pain patients that could benefit from targeting the pathway.
Content: Chronic pain patients suffer from inadequate treatment options and drug development is generally impaired by the low translatability of preclinical pain models.
Article Synopsis
- Drug discovery for epilepsy started with potassium bromide in 1857 and evolved through phenotypic screening tests, but current antiseizure medications still struggle with drug resistance and lack disease-modifying treatments.
- RNA-based drugs have emerged as a promising new approach to address these issues, targeting both noncoding RNAs and messenger RNAs to potentially modify diseases and overcome drug resistance.
- The paper discusses various therapeutic strategies using RNA therapeutics for different types of epilepsy, including sporadic cases, drug-resistant forms, and childhood monogenic epilepsies.
Background: Antiepileptic drugs, levetiracetam (LEV) and brivaracetam (BRV), bind to synaptic vesicle glycoprotein 2A (SV2A). In their anti-seizure activity, speed of brain entry may be an important factor. BRV showed faster entry into the human and non-human primate brain, based on more rapid displacement of SV2A tracer C-UCB-J.
View Article and Find Full Text PDFArticle Synopsis
- * The text highlights strategies for delivering these RNA-based drugs to the central nervous system (CNS) and discusses recent clinical advancements specifically for neurological and neuromuscular disorders.
- * Key abbreviations related to the topic include ALS for Amyotrophic Lateral Sclerosis, AD for Alzheimer's Disease, and CNS for Central Nervous System, indicating the range of conditions addressed by these innovative therapies.